开花店
2020-11-03
看好生物医药
@小牛快飞:
德琪医药,再一家生物科技公司,通过港交所聆讯
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
社区成长助手
2020-11-03
社区成长助手
终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看
老虎社区创作指引
什么也没有了~
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":306645060,"tweetId":"306645060","gmtCreate":1604393772150,"gmtModify":1703832819500,"author":{"id":3524106819480176,"idStr":"3524106819480176","authorId":3524106819480176,"authorIdStr":"3524106819480176","name":"开花店","avatar":"https://static.tigerbbs.com/d45a6be98c8265b24adce16054da5d87","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n看好生物医药</body></html>","htmlText":"<html><head></head><body>\n看好生物医药</body></html>","text":"看好生物医药","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/306645060","repostId":306683503,"repostType":1,"repost":{"magic":2,"id":306683503,"tweetId":"306683503","gmtCreate":1604378278102,"gmtModify":1703832754968,"author":{"id":3524106493041612,"idStr":"3524106493041612","authorId":3524106493041612,"authorIdStr":"3524106493041612","name":"小牛快飞","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/db56242c7fca08226f97f85ec7170c51"},{"img":"https://static.tigerbbs.com/860386e7bfe06239a389674beba9904a"}],"coverImages":[{"img":"https://static.tigerbbs.com/db56242c7fca08226f97f85ec7170c51"}],"title":"德琪医药,再一家生物科技公司,通过港交所聆讯","extraTitle":"","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/db56242c7fca08226f97f85ec7170c51\"></p><p>2020年11月2日,香港交易所披露了<strong>德琪医药有限公司Antengene CorporationLimited</strong>(以下简称“<strong>德琪医药</strong>”)同聆讯后的招股书,其将很快于香港主板上市。<strong>德琪医药</strong>此前于2020年8月26日递表。</p><p><strong>德琪医药</strong>是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司,公司的独特性来源于强大的研发能力以及开发新抗肿瘤疗法的战略方法。</p><p>截至最后实际可行日期,<strong>德琪医药</strong>已经战略性地设计并组建了12种治疗肿瘤药物资产的创新型管线,包括两种晚期临床资产(其由我们从Karyopharm及Celgene引进授权并作为我们的核心产品)、四种早期临床资产和六种临床前资产。截至同一日期,公司有九项正在进行的临床试验(包括三项研究者发起的试验)及五项计划启动的临床试验,并在亚太地区多个司法管辖区收到了九项IND批准。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/860386e7bfe06239a389674beba9904a\"></p><p>德琪医药招股书链接:</p><p>https://www1.hkexnews.hk/app/sehk/2020/102485/documents/sehk20110200007_c.pdf</p><p>版权声明:所有瑞恩资本Ryanben Capital的原创文章,转载须联系授权,并在文首/文末注明来源、作者、微信ID,否则瑞恩将向其追究法律责任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题,敬请原作者联系我们。</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/db56242c7fca08226f97f85ec7170c51\"></p><p>2020年11月2日,香港交易所披露了<strong>德琪医药有限公司Antengene CorporationLimited</strong>(以下简称“<strong>德琪医药</strong>”)同聆讯后的招股书,其将很快于香港主板上市。<strong>德琪医药</strong>此前于2020年8月26日递表。</p><p><strong>德琪医药</strong>是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司,公司的独特性来源于强大的研发能力以及开发新抗肿瘤疗法的战略方法。</p><p>截至最后实际可行日期,<strong>德琪医药</strong>已经战略性地设计并组建了12种治疗肿瘤药物资产的创新型管线,包括两种晚期临床资产(其由我们从Karyopharm及Celgene引进授权并作为我们的核心产品)、四种早期临床资产和六种临床前资产。截至同一日期,公司有九项正在进行的临床试验(包括三项研究者发起的试验)及五项计划启动的临床试验,并在亚太地区多个司法管辖区收到了九项IND批准。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/860386e7bfe06239a389674beba9904a\"></p><p>德琪医药招股书链接:</p><p>https://www1.hkexnews.hk/app/sehk/2020/102485/documents/sehk20110200007_c.pdf</p><p>版权声明:所有瑞恩资本Ryanben Capital的原创文章,转载须联系授权,并在文首/文末注明来源、作者、微信ID,否则瑞恩将向其追究法律责任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题,敬请原作者联系我们。</p></body></html>","text":"2020年11月2日,香港交易所披露了德琪医药有限公司Antengene CorporationLimited(以下简称“德琪医药”)同聆讯后的招股书,其将很快于香港主板上市。德琪医药此前于2020年8月26日递表。 德琪医药是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司,公司的独特性来源于强大的研发能力以及开发新抗肿瘤疗法的战略方法。 截至最后实际可行日期,德琪医药已经战略性地设计并组建了12种治疗肿瘤药物资产的创新型管线,包括两种晚期临床资产(其由我们从Karyopharm及Celgene引进授权并作为我们的核心产品)、四种早期临床资产和六种临床前资产。截至同一日期,公司有九项正在进行的临床试验(包括三项研究者发起的试验)及五项计划启动的临床试验,并在亚太地区多个司法管辖区收到了九项IND批准。 德琪医药招股书链接: https://www1.hkexnews.hk/app/sehk/2020/102485/documents/sehk20110200007_c.pdf 版权声明:所有瑞恩资本Ryanben Capital的原创文章,转载须联系授权,并在文首/文末注明来源、作者、微信ID,否则瑞恩将向其追究法律责任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题,敬请原作者联系我们。","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/306683503","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["06996"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":927,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":3765,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":2995626,"commentId":"2995626","gmtCreate":1604393930984,"gmtModify":1604393930984,"authorId":3527667803686145,"author":{"id":3527667803686145,"idStr":"3527667803686145","authorId":3527667803686145,"name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":306645060,"objectIdStr":"306645060","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看<a href=\"https://laohu8.com/TW/934879903\">老虎社区创作指引</a>","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看<a href=\"https://laohu8.com/TW/934879903\">老虎社区创作指引</a>","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看<a href=\"https://laohu8.com/TW/934879903\">老虎社区创作指引</a>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/306645060"}
精彩评论